CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Completed· 35 enrolled
Drug / intervention
Brimonidine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01144494
NCT01144494Early Ph 1Completed

Circadian Rhythms of Aqueous Humor Dynamics in Subjects With Ocular Hypertension Using Brimonidine

University of Nebraska·interventional·Posted Jun 15, 2010·Updated Nov 28, 2023

In Brief

A Early Phase 1 clinical trial evaluating Brimonidine and Artificial tears for Intraocular Pressure. Completed, enrolled 35 participants across 1 site.

Detailed Summary

This single-center, investigator-masked, crossover study is designed to investigate the circadian rhythms of aqueous humor dynamics in human subjects with ocular hypertension (OHT) before and after intervention with a commonly used ocular hypotensive medication, brimonidine for six weeks.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Early Ph 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJun 15, 2010
Enrollment StartAug 1, 2010
Primary CompletionOct 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 16.0 years ago

Interventions

Brimonidinedrug

One drop of brimonidine in each eye three times a day for six weeks.

Artificial tearsdrug

Lubricating drops added three times a day for six weeks